Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.
Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cattaneo R. Reyes-del Valle J, et al. Among authors: forest a. J Virol. 2012 Nov;86(21):11558-66. doi: 10.1128/JVI.01776-12. Epub 2012 Aug 15. J Virol. 2012. PMID: 22896607 Free PMC article.
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Gradishar WJ, et al. Among authors: forest a. Clin Cancer Res. 2016 Jan 15;22(2):301-9. doi: 10.1158/1078-0432.CCR-15-0588. Epub 2015 Aug 31. Clin Cancer Res. 2016. PMID: 26324738 Free PMC article. Clinical Trial.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
Novello S, Scagliotti G, de Castro G Jr, Kiyik M, Kowalyszyn R, Deppermann KM, Arriola E, Bosquee L, Novosiadly RD, Nguyen TS, Forest A, Tang S, Kambhampati SRP, Cosaert J, Reck M. Novello S, et al. Among authors: forest a. J Thorac Oncol. 2017 Feb;12(2):383-389. doi: 10.1016/j.jtho.2016.07.013. Epub 2016 Jul 25. J Thorac Oncol. 2017. PMID: 27464970 Free article. Clinical Trial.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M. Schaer DA, et al. Among authors: forest a. Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053. Cell Rep. 2018. PMID: 29539425 Free article.
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL. Shen Y, et al. Among authors: forest a. MAbs. 2015;7(5):931-45. doi: 10.1080/19420862.2015.1055442. MAbs. 2015. PMID: 26073904 Free PMC article.
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease.
Rioux JD, Boucher G, Forest A, Bouchard B, Coderre L, Daneault C, Frayne IR, Legault JT; iGenoMed Consortium; Bitton A, Ananthakrishnan A, Lesage S, Xavier RJ, Des Rosiers C. Rioux JD, et al. Among authors: forest a. medRxiv [Preprint]. 2024 Sep 22:2024.09.19.24314034. doi: 10.1101/2024.09.19.24314034. medRxiv. 2024. PMID: 39371119 Free PMC article. Preprint.
Blockage of ATGL-mediated breakdown of lipid droplets in microglia alleviates neuroinflammatory and behavioural responses to lipopolysaccharides.
Robb JL, Boisjoly F, Machuca-Parra AI, Coursan A, Manceau R, Majeur D, Rodaros D, Bouyakdan K, Greffard K, Bilodeau JF, Forest A, Daneault C, Ruiz M, Laurent C, Arbour N, Layé S, Fioramonti X, Madore C, Fulton S, Alquier T; Representative of consortium. Robb JL, et al. Among authors: forest a. Brain Behav Immun. 2025 Jan;123:315-333. doi: 10.1016/j.bbi.2024.09.027. Epub 2024 Sep 24. Brain Behav Immun. 2025. PMID: 39326768 Free article.
154 results